Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. has experienced notable stock performance, achieving a significant weekly increase and an impressive annual return. The company maintains strong financial health, highlighted by high operating cash flow and a low debt-equity ratio, indicating solid operational capabilities and stability in the pharmaceuticals sector.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. saw a significant rise on March 6, 2026, outperforming the China Shanghai Composite. Over the past year, the company achieved a 43.28% return, despite recent short-term challenges. With a market cap of CNY 19,816 million, it maintains strong financial metrics and a high dividend yield.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. faced a decline in stock performance, dropping 3.07% on March 3, 2026. Despite a year-to-date decrease, the company has shown strong resilience over the past year, with a return of 42.21%. Key financial metrics indicate a solid operational foundation.